CR Rate at 30 Mos Is a Feasible Surrogate Endpoint for PFS in First-line Follicular Lymphoma Trials

May 29-June 2, 2015; Chicago, Illinois
Results of a prospectively designed meta-analysis of a new surrogate endpoint that may expedite patient access to effective new therapies.
Format: Microsoft PowerPoint (.ppt)
File Size: 387 KB
Released: June 5, 2015


Educational grant provided by:
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Novartis Pharmaceuticals Corporation

Related Content

In this slideset from Clinical Care Options (CCO), experts provide insights on the optimal use of CAR T-cell therapy for lymphomas

person default Caron A. Jacobson, MD Released: June 16, 2021

Downloadable summary slideset of key takeaways from a live NCCN/CCO Webinar focused on current treatment in CLL/SLL.

Jeremy S. Abramson, MD, MMSc Anthony Mato, MD William G. Wierda, MD, PhD Released: June 15, 2021

From Clinical Care Options (CCO), video featuring expert insights on the integration of CAR T-cell therapy into community care

person default Caron A. Jacobson, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: June 14, 2021 Expired: June 13, 2022

Download these expert-selected slides on working with patients to manage their BTK inhibitor therapy, from Clinical Care Options (CCO).

Sandra E. Kurtin, PhD, ANP-C, AOCN Released: June 11, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.